News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
723,145 Results
Type
Article (40980)
Company Profile (267)
Press Release (681887)
Multimedia
Podcasts (82)
Webinars (17)
Section
Business (204691)
Career Advice (2026)
Deals (35539)
Drug Delivery (114)
Drug Development (81401)
Employer Resources (173)
FDA (16425)
Job Trends (14949)
News (346461)
Policy (32742)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2573)
Accelerated approval (37)
Adcomms (24)
Allergies (149)
Alliances (49577)
ALS (175)
Alzheimer's disease (1681)
Antibody-drug conjugate (ADC) (325)
Approvals (16705)
Artificial intelligence (538)
Autoimmune disease (164)
Automation (44)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (194)
Biotechnology (174)
Bladder cancer (164)
Brain cancer (58)
Breast cancer (650)
Cancer (4948)
Cardiovascular disease (410)
Career advice (1712)
Career pathing (37)
CAR-T (285)
CDC (49)
Celiac Disease (2)
Cell therapy (756)
Cervical cancer (37)
Clinical research (69725)
Collaboration (1750)
Company closure (4)
Compensation (1183)
Complete response letters (58)
COVID-19 (2717)
CRISPR (95)
C-suite (881)
Cystic fibrosis (143)
Data (6422)
Decentralized trials (2)
Denatured (25)
Depression (136)
Diabetes (510)
Diagnostics (6738)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (260)
Drug pricing (187)
Drug shortages (28)
Duchenne muscular dystrophy (239)
Earnings (90469)
Editorial (58)
Employer branding (21)
Employer resources (152)
Events (117666)
Executive appointments (990)
FDA (19622)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (24)
Funding (1504)
Gene editing (203)
Generative AI (44)
Gene therapy (612)
GLP-1 (978)
Government (4674)
Grass and pollen (6)
Guidances (385)
Healthcare (18888)
HIV (68)
Huntington's disease (47)
IgA nephropathy (84)
Immunology and inflammation (254)
Immuno-oncology (65)
Indications (127)
Infectious disease (3001)
Inflammatory bowel disease (196)
Inflation Reduction Act (14)
Influenza (123)
Intellectual property (258)
Interviews (316)
IPO (16648)
IRA (50)
Job creations (3643)
Job search strategy (1428)
JPM (57)
Kidney cancer (18)
Labor market (87)
Layoffs (547)
Leadership (33)
Legal (7951)
Liver cancer (92)
Longevity (17)
Lung cancer (668)
Lymphoma (384)
Machine learning (45)
Management (59)
Manufacturing (823)
MASH (166)
Medical device (13792)
Medtech (13852)
Mergers & acquisitions (19981)
Metabolic disorders (1292)
mRNA (159)
Multiple sclerosis (166)
NASH (16)
Neurodegenerative disease (330)
Neuropsychiatric disorders (89)
Neuroscience (2952)
Neurotech (1)
NextGen: Class of 2026 (6519)
Non-profit (4516)
Now hiring (69)
Obesity (607)
Opinion (266)
Ovarian cancer (168)
Pain (205)
Pancreatic cancer (237)
Parkinson's disease (290)
Partnered (33)
Patents (515)
Patient recruitment (518)
Peanut (59)
People (58968)
Pharmaceutical (62)
Pharmacy benefit managers (30)
Phase 1 (21737)
Phase 2 (30686)
Phase 3 (22865)
Pipeline (5764)
Policy (293)
Postmarket research (2564)
Preclinical (9214)
Press Release (64)
Prostate cancer (253)
Psychedelics (48)
Radiopharmaceuticals (289)
Rare diseases (878)
Real estate (5956)
Recruiting (70)
Regulatory (24628)
Reports (53)
Research institute (2395)
Resumes & cover letters (353)
Rett syndrome (29)
RNA editing (16)
RSV (81)
Schizophrenia (150)
Series A (249)
Series B (192)
Service/supplier (11)
Sickle cell disease (101)
Special edition (22)
Spinal muscular atrophy (158)
Sponsored (42)
Startups (3617)
State (2)
Stomach cancer (18)
Supply chain (106)
Tariffs (84)
The Weekly (55)
Vaccines (1018)
Venture capital (89)
Weight loss (389)
Women's health (98)
Worklife (19)
Date
Last 7 days (873)
Last 30 days (2677)
Last 365 days (29798)
2026 (4852)
2025 (30172)
2024 (35215)
2023 (40075)
2022 (51178)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35023)
2017 (32113)
2016 (31483)
2015 (37553)
2014 (31318)
2013 (26346)
2012 (28571)
2011 (29266)
2010 (27328)
Location
Africa (736)
Alabama (86)
Alaska (7)
Arizona (315)
Arkansas (13)
Asia (39286)
Australia (6422)
California (11610)
Canada (3353)
China (1119)
Colorado (488)
Connecticut (489)
Delaware (342)
Europe (84720)
Florida (1746)
Georgia (370)
Hawaii (3)
Idaho (61)
Illinois (886)
India (70)
Indiana (536)
Iowa (22)
Japan (442)
Kansas (127)
Kentucky (42)
Louisiana (27)
Maine (72)
Maryland (1413)
Massachusetts (8291)
Michigan (335)
Minnesota (635)
Mississippi (6)
Missouri (129)
Montana (32)
Nebraska (29)
Nevada (125)
New Hampshire (80)
New Jersey (3082)
New Mexico (28)
New York (3053)
North Carolina (1483)
North Dakota (8)
Northern California (5702)
Ohio (346)
Oklahoma (21)
Oregon (41)
Pennsylvania (2342)
Puerto Rico (24)
Rhode Island (49)
South America (1108)
South Carolina (68)
South Dakota (1)
Southern California (4529)
Tennessee (179)
Texas (1786)
United States (41076)
Utah (350)
Vermont (1)
Virginia (270)
Washington D.C. (81)
Washington State (937)
West Virginia (4)
Wisconsin (112)
Wyoming (2)
723,145 Results for "ascletis inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development
February 11, 2026
·
4 min read
Press Releases
Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
January 20, 2026
·
4 min read
Press Releases
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
January 29, 2026
·
3 min read
Press Releases
Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes
January 26, 2026
·
4 min read
Press Releases
Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes
January 5, 2026
·
4 min read
Press Releases
Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
December 1, 2025
·
4 min read
Press Releases
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
December 10, 2025
·
3 min read
Press Releases
Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration
October 15, 2025
·
2 min read
Press Releases
Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor
December 15, 2025
·
4 min read
Press Releases
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
February 2, 2026
·
8 min read
1 of 72,315
Next
